Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0RHPMN |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | A humanized anti-Nectin-4 IgG1 Fc-silent mAb |
|||||
| Antigen Name | nectin-4 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LY4052031 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants include those with specific solid tumors (separate cohort requirements apply), ECOG 0-1, and adequate tumor tissue availability. Major exclusions include uncontrolled CNS metastases, cardiovascular disease, severe prior toxicities, QTcF ≥470 ms, and active corneal/pulmonary conditions, with additional enfortumab vedotin-related restrictions for certain cohorts.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06465069 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
|
||||
| Primary Endpoint |
Phase 1a aims to determine the Recommended Phase 2 Dose (RP2D) of LY4052031 by evaluating dose-limiting toxicities (DLTs) within Cycle 1 (21 days). Phase 1b assesses antitumor activity through Overall Response Rate (ORR) per RECIST 1.1 over approximately 48 months.
|
||||
| Other Endpoint |
Key evaluations include pharmacokinetics (PK) parameters (Cmin, AUC) during Cycle 1 and antitumor activity metrics (ORR, DOR, TTR, PFS, DCR, OS) per RECIST 1.1 tracked over 48 months to comprehensively characterize LY4052031's clinical profile.
|
||||
References